Loading
Kidney Failure, Chronic / Factor Xa Inhibitors / Stroke · Journal article
Renal Failure · May 13, 2026
Encouraging direction, but not yet definitive.
This meta-analysis pooling 3 RCTs and 8 observational studies demonstrates that apixaban and rivaroxaban are associated with substantially lower bleeding risks (major, GI, and intracranial) compared with warfarin in atrial fibrillation patients on dialysis. Efficacy endpoints (stroke/systemic embolism and all-cause mortality) showed numerically favorable trends but were accompanied by substantial heterogeneity, and statistical significance was not achieved in RCT-only subgroup analysis, limiting definitive conclusions about clinical benefit.
Systematic review and meta-analysis of 3 randomized controlled trials and 8 observational studies. Patients with atrial fibrillation undergoing dialysis (ESRD); studies compared apixaban or rivaroxaban with vitamin K antagonists.. Intervention: Apixaban or rivaroxaban (standard- and low-dose regimens examined in exploratory analyses).. Compared with: Vitamin K antagonists (VKAs), primarily warfarin..
Major bleeding RR 0.57 (95% CI: 0.51–0.63) with apixaban/rivaroxaban versus VKAs Gastrointestinal bleeding RR 0.66 (95% CI: 0.57–0.76) with apixaban/rivaroxaban versus VKAs Intracranial hemorrhage RR 0.54 (95% CI: 0.36–0.83) with apixaban/rivaroxaban versus VKAs
Major bleeding RR 0.57 (95% CI: 0.51–0.63) with apixaban/rivaroxaban versus VKAs Gastrointestinal bleeding RR 0.66 (95% CI: 0.57–0.76) with apixaban/rivaroxaban versus VKAs
The bleeding safety profile of apixaban and rivaroxaban appears superior to warfarin in this high-risk dialysis population. However, clinicians should note that efficacy claims (stroke prevention and mortality reduction) remain inconclusive due to heterogeneity and underpowered RCT subgroup analysis; large prospective RCTs are needed before firm recommendations can guide anticoagulation choice in AF patients with ESRD.
Meta-analysis of 3 RCTs and 8 observational studies shows apixaban and rivaroxaban associated with lower bleeding risk versus warfarin in dialysis patients with AF, but efficacy endpoints show substantial heterogeneity and RCT-only analysis lacked statistical significance; evidence is suggestive but requires dedicated large RCTs.
As stated by the source record.
Quoted from the source exactly as published.
The bleeding safety profile of apixaban and rivaroxaban appears superior to warfarin in this high-risk dialysis population. However, clinicians should note that efficacy claims (stroke prevention and mortality reduction) remain inconclusive due to heterogeneity and underpowered RCT subgroup analysis; large prospective RCTs are needed before firm recommendations can guide anticoagulation choice in AF patients with ESRD.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This study aimed to evaluate the comparative efficacy and safety of apixaban and rivaroxaban versus vitamin K antagonists (VKAs) in anticoagulation management in a dialysis population. PubMed, Embase, and the Cochrane Library were searched for studies comparing apixaban or rivaroxaban with VKAs in patients with atrial fibrillation (AF) undergoing dialysis. The primary efficacy endpoints included stroke/systemic embolism (SSE) and all-cause mortality. Safety outcomes encompassed major bleeding, intracranial hemorrhage, and gastrointestinal bleeding. Risk ratios (RR) with 95% confidence intervals (CI) were synthesized using random-effects models. The meta-analysis included three randomized controlled trials (RCTs) and eight observational studies. Pooled analyses showed that apixaban and rivaroxaban were associated with lower risks of major bleeding (RR 0.57, 95% CI: 0.51-0.63), gastrointestinal bleeding (RR 0.66, 95% CI: 0.57-0.76), and intracranial hemorrhage (RR 0.54, 95% CI: 0.36-0.83) compared with VKAs. Additionally, apixaban and rivaroxaban were associated with reduced risk of SSE (RR 0.57, 95% CI: 0.46-0.72) and all-cause mortality (RR 0.73, 95% CI:0.63-0.83), although substantial heterogeneity was present. Exploratory dose-stratified analyses suggested both standard- and low-dose apixaban regimens were associated with favorable efficacy and hemostatic safety relative to warfarin. Consistent numerical trends were observed in the RCT-only analysis, though none reached statistical significance owing to limited sample size. In conclusion, apixaban and rivaroxaban are associated with lower risks of bleeding compared with VKAs in patients with AF and ESRD. However, evidence regarding their efficacy in preventing SSE, all-cause mortality and the optimal apixaban dosing regimen remains inconclusive and requires validation in large, dedicated RCTs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.